MaxCyte Inc
MaxCyte Inc (MXCT) Covered Calls
As of September 18, 2026, MXCT has 2 covered call opportunities in the coming three months. Return ranges from 114.3 to 118.5% until expiration. Annualized return ranges from 205.9 to 350.5%. The nearest expiration is January 15, 2027. Maximum potential profit is $141.
Read more
Running MXCT covered calls helps you generate consistent income from MaxCyte Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on MaxCyte Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best MXCT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if MXCT stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling MXCT covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given MaxCyte Inc covered call is worth writing.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Income-focused investors, long-term MXCT holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling MXCT covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best MaxCyte Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV percentile34.92% Neutral
- Market cap (M$)123
- 52 weeks high-36.02%
- 52 weeks low85.94%
- Analyst recommendationStrong Buy
1.33 - Target price$4.10
244.54% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-11
- P/E—
- Future P/E—
- EPS (ttm)-0.33
- EPS growth next 5 years21.91%
As of September 18, 2026
| 2027-01-15 | 119 | 2.50 | 110.08 | 0.05 | 0.95 | 136.00 | 114.29 | 350.54 | -4.20 | +0.64 | 175 | 0.90 |
| 2027-04-16 | 210 | 2.50 | 110.08 | 0.10 | 0.75 | 141.00 | 118.49 | 205.94 | -8.40 | +0.59 | 0 | 0.65 |
As of September 18, 2026
Sell covered calls with the data behind you
Find the best MXCT covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→